FDA approves Purdue's oxycodone

|By:, SA News Editor

The FDA approves Purdue Pharmaceuticals' Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets) for the treatment of severe pain requiring around-the-clock long-term opioids where alternative treatment options are inadequate.

Targiniq incorporates abuse deterrent technology. When a pill is crushed and/or dissolved (for snorting or injecting) the naloxone blocks the euphoric effects of oxycodone making it less desirable for abusers than oxycodone alone.

The agency requires a postmarket study to assess the risks of long-term use beyond 12 weeks and the effects of the abuse deterrent features.

Related tickers: (NASDAQ:ZGNX) (NYSE:ABBV) (NYSE:TEVA) (NASDAQ:ALKS) (NYSE:MNK) (NYSE:PFE)